Nuclear receptor ligands in inflammatory lung diseases
作者： Lakshman Ramamurthy , Ryan P. Trump
DOI: 10.1016/J.DDMEC.2006.03.001
关键词:
摘要: Inflammation is an underlying feature of several prevalent lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). The inflammatory response a cascade events in which the expression proinflammatory genes essential. Some these transcriptional are regulated by nuclear receptor (NR) family ligand-activated transcription factors. glucocorticoid (GR) already validated NR target for suppression asthma, whereas anti-inflammatory properties other NRs only now being explored. This article reviews role mechanisms multiple modulating their potential treatment diseases.
elsevier.com
sci-hub.se 参考文章(37)
N. Auphan, J. A. DiDonato, C. Rosette, A. Helmberg, M. Karin, Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis Science. ,vol. 270, pp. 286- 290 ,(1995) , 10.1126/SCIENCE.270.5234.286
Maria G. Belvisi, Sharon L. Wicks, Clifford H. Battram, Stephen E. W. Bottoms, Jane E. Redford, Paul Woodman, Thomas J. Brown, Stephen E. Webber, Martyn L. Foster, Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. Journal of Immunology. ,vol. 166, pp. 1975- 1982 ,(2001) , 10.4049/JIMMUNOL.166.3.1975
Timothy M. Willson, Millard H. Lambert, Steven A. Kliewer, Peroxisome proliferator-activated receptor γ and metabolic disease Annual Review of Biochemistry. ,vol. 70, pp. 341- 367 ,(2001) , 10.1146/ANNUREV.BIOCHEM.70.1.341
Cynthia Mueller, Veronika Weaver, John P Vanden Heuvel, Avery August, Margherita T Cantorna, Peroxisome proliferator-activated receptor γ ligands attenuate immunological symptoms of experimental allergic asthma Archives of Biochemistry and Biophysics. ,vol. 418, pp. 186- 196 ,(2003) , 10.1016/J.ABB.2003.08.006
Jeffrey N Miner, Mei Hua Hong, Andrés Negro-Vilar, New and improved glucocorticoid receptor ligands. Expert Opinion on Investigational Drugs. ,vol. 14, pp. 1527- 1545 ,(2005) , 10.1517/13543784.14.12.1527
Juliane Platz, Robert Bals, Novel Drugs for Inflammatory Lung Diseases Current Medicinal Chemistry - Anti-inflammatory & Anti-allergy Agents. ,vol. 3, pp. 39- 52 ,(2004) , 10.2174/1568014043483580
K PATEL, K WRIGHT, P WHITTAKER, P CHAKRAVARTY, M WATSON, S WARD, Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPARγ agonists : Evidence for disparate functional effects which are independent of NF-κB and PPARγ Cellular Signalling. ,vol. 17, pp. 1098- 1110 ,(2005) , 10.1016/J.CELLSIG.2004.12.002
Peter Cheng, Ranjan Mukherjee, PPARs as targets for metabolic and cardiovascular diseases. Mini-reviews in Medicinal Chemistry. ,vol. 5, pp. 741- 753 ,(2005) , 10.2174/1389557054553758
Hideyuki Migita, Noboru Satozawa, Jiing-Huey Lin, John Morser, Kohichi Kawai, RORα1 and RORα4 suppress TNF-α-induced VCAM-1 and ICAM-1 expression in human endothelial cells FEBS Letters. ,vol. 557, pp. 269- 274 ,(2004) , 10.1016/S0014-5793(03)01502-3
Albert S. Baldwin, Series Introduction: The transcription factor NF-κB and human disease Journal of Clinical Investigation. ,vol. 107, pp. 3- 6 ,(2001) , 10.1172/JCI11891